弥漫大B细胞淋巴瘤患者临床特征及预后分析

赵洁, 姜言, 郝思国

Clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma

ZHAO Jie, JIANG Yan, HAO Siguo

表2 DLBCL患者近期疗效分析

Tab 2 Analysis of short-term efficacy of patients with DLBCL

Variable Overall response rate (CR+PR) Patients/n(%) P value Gender Male 74/88 (84.1) 0.381 Female 64/72 (88.9) Age ≤60 years 69/73 (94.5) 0.005 >60 years 69/87 (79.3) Group B symptoms No 79/87 (90.8) 0.068 Yes 59/73 (80.8) Hans classification GCB 51/56 (91.1) 0.194 Non-GCB 87/104 (89.7) ECOG score <2 scores 104/117 (88.9) 0.110 ≥2 scores 34/43 (79.1) Ann Arbor stage Ⅰ‒Ⅱ 57/63 (90.5) 0.211 Ⅲ‒Ⅳ 81/97 (83.5) IPI score 0‒2 scores 65/70 (92.9) 0.032 3‒5 scores 73/90 (81.1) LDH level ≤211 U·L-1 47/51 (92.2) 0.138 >211 U·L-1 91/109 (83.5) Albumin level ≥35 g·L-1 112/123 (91.1) 0.001 <35 g·L-1 26/37 (70.3) Absolute lymphocyte level >1.1×109·L-1 93/104 (89.4) 0.112 ≤1.1×109·L-1 45/56 (80.4) Anemia No 97/106 (91.5) 0.007 Yes 41/54 (75.9) Chemotherapy regimen R-CHOP 126/147 (85.7) 0.508 CHOP 12/13 (92.3)